157 related articles for article (PubMed ID: 2495893)
1. Plasma levonorgestrel levels and ovarian function during the use of a levonorgestrel-releasing intracervical contraceptive device.
Ratsula K; Toivonen J; Lähteenmäki P; Luukkainen T
Contraception; 1989 Feb; 39(2):195-204. PubMed ID: 2495893
[TBL] [Abstract][Full Text] [Related]
2. Effect of levonorgestrel-releasing intrauterine device on hormonal profile and menstrual pattern after long-term use.
Xiao B; Zeng T; Wu S; Sun H; Xiao N
Contraception; 1995 Jun; 51(6):359-65. PubMed ID: 7554977
[TBL] [Abstract][Full Text] [Related]
3. The effect of deliberate omission of Trinordiol or Microgynon on the hypothalamo-pituitary-ovarian axis.
Smith SK; Kirkman RJ; Arce BB; McNeilly AS; Loudon NB; Baird DT
Contraception; 1986 Nov; 34(5):513-22. PubMed ID: 3102162
[TBL] [Abstract][Full Text] [Related]
4. Intracervical and fundal administration of levonorgestrel for contraception: endometrial thickness, patterns of bleeding, and persisting ovarian follicles.
Pakarinen PI; Suvisaari J; Luukkainen T; Lähteenmäki P
Fertil Steril; 1997 Jul; 68(1):59-64. PubMed ID: 9207585
[TBL] [Abstract][Full Text] [Related]
5. Ovarian function during use of a levonorgestrel-releasing IUD.
Barbosa I; Bakos O; Olsson SE; Odlind V; Johansson ED
Contraception; 1990 Jul; 42(1):51-66. PubMed ID: 2117516
[TBL] [Abstract][Full Text] [Related]
6. Acceptability of an experimental intracervical device: results of a study controlling for selection bias.
Shain RN; Ratsula K; Toivonen J; Lähteenmäki P; Luukkainen T; Holden AE; Rosenthal M
Contraception; 1989 Jan; 39(1):73-84. PubMed ID: 2491982
[TBL] [Abstract][Full Text] [Related]
7. Levonorgestrel plasma concentrations and hormone profiles after insertion and after one year of treatment with a levonorgestrel-IUD.
Nilsson CG; Lähteenmäki P; Luukkainen T
Contraception; 1980 Mar; 21(3):225-33. PubMed ID: 6771090
[TBL] [Abstract][Full Text] [Related]
8. Blood levels of levonorgestrel in women following vaginal placement of contraceptive pills.
Alvarez F; Faundes A; Johansson E; Coutinho E
Fertil Steril; 1983 Jul; 40(1):120-3. PubMed ID: 6407876
[TBL] [Abstract][Full Text] [Related]
9. Effects of a sequential regimen of mifepristone-medroxyprogesterone acetate on ovarian function, endometrial development and hormonal parameters.
Croxatto HB; Massai MR; Salvatierra AM; Fuentealba B; Croxatto HD; Lähteenmäki P
Contraception; 1996 Aug; 54(2):79-86. PubMed ID: 8842583
[TBL] [Abstract][Full Text] [Related]
10. Sonographic assessment of ovarian and endometrial changes during long-term Norplant use and their correlation with hormonal levels.
Shaaban MM; Segal S; Salem HT; Ghaneimah SA; Khalifa EA; Ahmed AG
Fertil Steril; 1993 May; 59(5):998-1002. PubMed ID: 8486202
[TBL] [Abstract][Full Text] [Related]
11. Ovarian endocrine function through five years of continuous treatment with NORPLANT subdermal contraceptive implants.
Brache V; Alvarez-Sanchez F; Faundes A; Tejada AS; Cochon L
Contraception; 1990 Feb; 41(2):169-77. PubMed ID: 2107058
[TBL] [Abstract][Full Text] [Related]
12. Suppression of ovarian function with the transdermally given synthetic progestin ST 1435.
Laurikka-Routti M; Haukkamaa M; Lähteenmäki P
Fertil Steril; 1992 Oct; 58(4):680-4. PubMed ID: 1426309
[TBL] [Abstract][Full Text] [Related]
13. Effective contraception with the levonorgestrel-releasing intrauterine device: 12-month report of a European multicenter study.
Luukkainen T; Allonen H; Haukkamaa M; Holma P; Pyörälä T; Terho J; Toivonen J; Batar I; Lampe L; Andersson K
Contraception; 1987 Aug; 36(2):169-79. PubMed ID: 3123132
[TBL] [Abstract][Full Text] [Related]
14. Ovulatory dysfunction during continuous administration of low-dose levonorgestrel by subdermal implants.
Faundes A; Brache V; Tejada AS; Cochon L; Alvarez-Sanchez F
Fertil Steril; 1991 Jul; 56(1):27-31. PubMed ID: 1906017
[TBL] [Abstract][Full Text] [Related]
15. Plasma progesterone levels during long-term treatment with levonorgestrel silastic implants.
Croxatto HB; Diaz S; Pavez M; Miranda P; Brandeis A
Acta Endocrinol (Copenh); 1982 Oct; 101(2):307-11. PubMed ID: 6814139
[TBL] [Abstract][Full Text] [Related]
16. Intracervical release of levonorgestrel for contraception.
Kurunmäki H; Toivonen J; Lähteenmäki P; Luukkainen T
Contraception; 1981 May; 23(5):473-85. PubMed ID: 6793299
[TBL] [Abstract][Full Text] [Related]
17. Lipid effects of an intrauterine levonorgestrel device or oral vs. vaginal natural progesterone in post-menopausal women treated with percutaneous estradiol.
Suvanto-Luukkonen E; Sundström H; Penttinen J; Kauppila A
Arch Gynecol Obstet; 1998; 261(4):201-8. PubMed ID: 9789651
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of folliculogenesis and ovulation by the antiprogesterone RU 486.
Luukkainen T; Heikinheimo O; Haukkamaa M; Lähteenmäki P
Fertil Steril; 1988 Jun; 49(6):961-3. PubMed ID: 3371492
[TBL] [Abstract][Full Text] [Related]
19. Clinical performance of a levonorgestrel-releasing intracervical contraceptive device during the first two years of use.
Ratsula K
Contraception; 1989 Feb; 39(2):187-93. PubMed ID: 2495892
[TBL] [Abstract][Full Text] [Related]
20. A clinical pharmacological study of a new type of vaginal delivery system for levonorgestrel.
Landgren BM; Johannisson E; Xing S; Aedo AR; Diczfalusy E
Contraception; 1985 Dec; 32(6):581-601. PubMed ID: 3937664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
